Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,850 result(s) found for: Breast cancer. Displaying page 4 of 93.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-002016-26 Sponsor Protocol Number: FBCSG-01-2007 Start Date*: 2007-08-08
    Sponsor Name:Finnish Breast Cancer Group
    Full Title: A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant ...
    Medical condition: Invasive early breast cancer that has been removed by surgery.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) SE (Completed) GB (GB - no longer in EU/EEA) IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014279-37 Sponsor Protocol Number: ML22780 Start Date*: 2009-12-07
    Sponsor Name:Roche Products Limited
    Full Title: Open-Label study of bevacizumab (Avastin®) and taxane monotherapy for the first-line treatment of patients with advanced triple-negative breast cancer
    Medical condition: Advanced triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002532-24 Sponsor Protocol Number: HER2 PG study Start Date*: 2007-05-10
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Pharmacogenetic study of FcγRIIIa and HER2 genes in relation to treatment of breast cancer
    Medical condition: Breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006203 Breast cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004610-35 Sponsor Protocol Number: AL-2001 Start Date*: 2021-03-16
    Sponsor Name:Allarity Therapeutics Europe Aps
    Full Title: Phase II, open label, single arm study to investigate anti-tumor effect of ixabepilone in patients with locally recurrent metastatic breast cancer (mBC) selected by the ixabepilone Drug Response Pr...
    Medical condition: Locally recurrent or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PL (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000764-42 Sponsor Protocol Number: UC-0140/1606 Start Date*: 2016-10-12
    Sponsor Name:UNICANCER
    Full Title: A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration Afte...
    Medical condition: Patients with ER+ and HER2- primary non-metastatic breast cancer who are eligible to neoadjuvant endocrine therapy.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-009418-42 Sponsor Protocol Number: INT-07/09 Start Date*: 2009-05-19
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study evaluating efficacy and tolerability of Sorafenib in the treatment of iatrogenic lymphedema occurring in breast cancer patients following surgical dissection of, and/or radiotherapy ...
    Medical condition: Breast cancer patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004909-33 Sponsor Protocol Number: LCTU122 Start Date*: 2015-09-21
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: Thrombin Inhibition Preoperatively in Early Breast Cancer
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001296-67 Sponsor Protocol Number: CBFU Start Date*: 2016-07-26
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: DUAL ENERGY CONTRAST ENHANCED DIGITAL MAMMOGRAPHY PERFORMANCE EVALUATION IN COMPARISON OF CONVENTIONAL DIGITAL MAMMOGRAPHY, TOMOSINTESIS AND MR IMAGING IN WOMEN FOLLOW-UP FOR BREAST CARCINOMA
    Medical condition: WOMAN WITH BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10006206 Breast carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002717-35 Sponsor Protocol Number: MDV3100-12 Start Date*: 2013-11-26
    Sponsor Name:Medivation, Inc.
    Full Title: A Phase 2, Randomized, Double Blind, Placebo Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estr...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-002508-42 Sponsor Protocol Number: SBMASTER Start Date*: 2019-12-19
    Sponsor Name:Aarhus University Hospital
    Full Title: A randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early ...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005337-37 Sponsor Protocol Number: ONC-2012-002 Start Date*: 2013-05-07
    Sponsor Name:Istituto Clinico Humanitas
    Full Title: ANTI-MULLERIAN HORMONE (AMH) AS A MARKER OF OVARIAN RESERVE IN YOUNG BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY + GnRH ANALOGUE
    Medical condition: Female subjects, aged <40yrs receiving adjuvant chemotherapy and ovarian suppression by means of GnRHa with the aim to assess the role of AMH as surrogate marker of the preservation of ovarian rese...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006203 Breast cancer stage unspecified LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003194-28 Sponsor Protocol Number: PULSION-001 Start Date*: 2011-10-24
    Sponsor Name:PULSION Medical Systems SE
    Full Title: Determination of the sensitivity of ICG fluorescence technique for the detection of Sentinel Lymph Nodes in breast cancer – a monocenter, prospective open-label clinical trial
    Medical condition: Breast cancer with indicated sentinel lymph node biopsy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004503-23 Sponsor Protocol Number: CS-2015-1 Start Date*: 2015-12-17
    Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nucelar Medicine and PET
    Full Title: Phase II trial: uPAR-PET for preoperative staging of breast cancer patients
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-003995-23 Sponsor Protocol Number: GBG52 Start Date*: 2009-03-31
    Sponsor Name:GBG Forschungs GmbH
    Full Title: An investigational randomized phase II-(III) study on epirubicin plus cyclophospamide (or CMF) vs nab-paclitaxel plus capecitabine as adjuvant chemotherapy for elderly non frail patients with an in...
    Medical condition: Primary breast cancer at non-frail, eldery male and female patients
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000987-18 Sponsor Protocol Number: TRAIN Start Date*: 2008-07-10
    Sponsor Name:Netherlands Cancer Institute
    Full Title: Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study
    Medical condition: HER2 positive breat cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006473-24 Sponsor Protocol Number: EFC10073 Start Date*: 2007-07-03
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A randomized, open-label, multi-center study of larotaxel at 90mg/m² or docetaxel every 3 weeks, alone or in combination with trastuzumab according to Her2neu status, administered after a combinati...
    Medical condition: high risk localized breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000436-27 Sponsor Protocol Number: BR3031 Start Date*: 2007-02-16
    Sponsor Name:University of Birmingham [...]
    1. University of Birmingham
    2. University Hospital Birmingham NHS Foundation Trust
    Full Title: Neoadjuvant trial of pre-operative exemestane or letrozole +/-celecoxib in the treatment of ER positive postmenopausal early breast cancer.
    Medical condition: Postmenopausal early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-022077-33 Sponsor Protocol Number: CaPaBe Start Date*: 2011-01-20
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: Phase II, open label, study of primary chemotherapy with Bevacizumab in association with carboplatin, paclitaxel in early and locally advanced triple negative (ER, PgR and HER2 negative) breast ca...
    Medical condition: Patient with early and locally advanced triple negative (ER, PgR and HER2 negative) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002173-28 Sponsor Protocol Number: C4391002 Start Date*: 2023-01-25
    Sponsor Name:Pfizer Inc.
    Full Title: PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMB...
    Medical condition: HR-positive HER2-negative metastatic/advanced BC
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002505-35 Sponsor Protocol Number: ABCSG_50 Start Date*: 2018-06-25
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline...
    Medical condition: Prevention of breast cancer in women with a BRCA1 germline mutation
    Disease: Version SOC Term Classification Code Term Level
    21.0 10042613 - Surgical and medical procedures 10036898 Prophylaxis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    23.0 10010331 - Congenital, familial and genetic disorders 10071980 BRCA1 gene mutation PT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 05:15:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA